Impaired hepatic removal of galectin–3 and association with worse liver function in patients with alcoholic liver cirrhosis

Buechler, Christa; Wiest, Reiner; Bauer, Sabrina; Wanninger, Josef; Neumeier, Markus; Farkas, S.; Scherer, M.; Schaeffler, Andreas

doi:10.1055/s-0030-1269458

Cited by 12 publications

(31 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circulating adiponectin levels show a gender disparity and are higher in females than males. Adiponectin is almost exclusively produced in adipocytes, and in the obese, reduced expression in fat cells correlates with a decline in adiponectin serum levels [ 21 , 53 ]. Low adiponectin levels in obesity contribute to insulin resistance and NAFLD [ 52 , 54 , 55 , 56 , 57 ] and are a risk factor for malignant diseases, making adiponectin receptor agonists potential drug candidates for cancer treatment [ 58 ].…”

Section: Adipokines In Urine and Fecesmentioning

confidence: 99%

“…Though not used in clinical routine diagnostics to date, serum levels of distinct adipokines are now well believed to represent excellent biomarkers for metabolic diseases such as insulin resistance or non-alcoholic fatty liver disease (NAFLD) [ 18 , 19 , 20 , 21 ]. Furthermore, adipokines can also be found in urine and feces, which are easily accessible and provide an opportunity to establish cost-effective, non-invasive tests.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Fecal and Urinary Adipokines as Disease Biomarkers

et al. 2023

View full text Add to dashboard Cite

The use of biomarkers is of great clinical value for the diagnosis and prognosis of disease and the assessment of treatment efficacy. In this context, adipokines secreted from adipose tissue are of interest, as their elevated circulating levels are associated with a range of metabolic dysfunctions, inflammation, renal and hepatic diseases and cancers. In addition to serum, adipokines can also be detected in the urine and feces, and current experimental evidence on the analysis of fecal and urinary adipokine levels points to their potential as disease biomarkers. This includes increased urinary adiponectin, lipocalin-2, leptin and interleukin-6 (IL-6) levels in renal diseases and an association of elevated urinary chemerin as well as urinary and fecal lipocalin-2 levels with active inflammatory bowel diseases. Urinary IL-6 levels are also upregulated in rheumatoid arthritis and may become an early marker for kidney transplant rejection, while fecal IL-6 levels are increased in decompensated liver cirrhosis and acute gastroenteritis. In addition, galectin-3 levels in urine and stool may emerge as a biomarker for several cancers. With the analysis of urine and feces from patients being cost-efficient and non-invasive, the identification and utilization of adipokine levels as urinary and fecal biomarkers could become a great advantage for disease diagnosis and predicting treatment outcomes. This review article highlights data on the abundance of selected adipokines in urine and feces, underscoring their potential to serve as diagnostic and prognostic biomarkers.

show abstract

Section: Adipokines In Urine and Fecesmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Fecal and Urinary Adipokines as Disease Biomarkers

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Adiponectin’s role in appetite regulation is not fully elucidated, as studies indicate both anorexigenic and orexigenic effects [ 8 ]. Several studies provide evidence that adipokines may affect adrenal steroid secretion or impact their metabolism in the liver [ 25 , 26 , 27 , 28 ].…”

Section: Introductionmentioning

confidence: 99%

The Impact of Obesity on the Excretion of Steroid Metabolites in Boys and Girls: A Comparison with Normal-Weight Children

et al. 2023

View full text Add to dashboard Cite

Obesity in childhood is associated with several steroid changes, which result from excess body mass. The aim of this study was to evaluate steroid metabolism in children with obesity compared with those with normal weight, especially in relation to sex and puberty progress. We analyzed the clinical data of 191 children, aged between 5 and 18 years, with 115 affected (64 girls and 51 boys) and 76 unaffected (35 girls and 41 boys) by obesity. Routine clinical assessment and pubertal stage evaluation based upon Tanner’s scale were performed. In addition, to evaluate the impact of puberty, children with pre-adolescence and advanced puberty were divided into separate subgroups. Then, 24 h urine steroid excretion profiles were analyzed by gas chromatography/mass spectrometry. Significant differences in the excretion of steroid metabolites were found between normal weight children and children with obesity, especially in the prepubertal cohort. In this group, we observed enhanced activity in all the pathways of adrenal steroidogenesis. Raised excretion of mineralocorticoid derivatives such as tetrahydro-11-deoxycorticosterone, tetrahydrocorticosterone, and 5α-tetrahydrocorticosterone supported increased activity of this track. No significant differences were detected in the excreted free forms of cortisol and cortisone, while the excretion of their characteristic tetrahydro-derivatives was different. In pre-adolescent children with obesity, α-cortol and especially α-cortolone appeared to be excreted more abundantly than β-cortol or β-cortolone. Furthermore, in children with obesity, we observed elevated androgen excretion with an enhanced backdoor pathway. As puberty progressed, remarkable reduction in the differences between adolescents with and without obesity was demonstrated.

show abstract

“…[7] Studies also indicated that ADPN appears to play an important role in the pathogenesis of chronic liver disease, related inflammation and liver damages by affecting lipid metabolism. [8] Several studies have suggested a hepatoprotective effect of ADPN against MAFLD. [8] However, the underlying mechanisms have not been fully elucidated yet.…”

Section: Introductionmentioning

confidence: 99%

“…[8] Several studies have suggested a hepatoprotective effect of ADPN against MAFLD. [8] However, the underlying mechanisms have not been fully elucidated yet.…”

Section: Introductionmentioning

confidence: 99%

Pectic Oligogalacturonide Facilitates the Synthesis and Activation of Adiponectin to Improve Hepatic Lipid Oxidation

Chen

Sun

et al. 2021

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Scope: Adiponectin (ADPN), a kind of adipokines, plays an important role in the regulation of lipid metabolism. The objective of this study is focused on the ADPN to investigate the functional mechanisms of pectin oligosaccharide (POS) from hawthorn fruit in the improvement of hepatic fatty acid oxidation. Method and Results: High-fat fed mice are used in this experiment. POS is administrated with the doses of 0.25, 0.75, and 1.5 g kg −1 diet, respectively. The results demonstrate that gene and protein expressions of ADPN synthesis regulators involved in PKA/ERK/CREB and C/EBP𝜶/PPAR𝜸 pathways are upregulated by POS administration. POS also activates the AdiopR1/AMPK𝜶/PGC1 and AdipoR2/PPAR𝜶 signaling pathways to improve the fatty acid oxidation in the liver, which is further accelerated by the enhancement of mitochondrial functions. Conclusion: POS can act as an ADPN activator to improve lipid metabolism, leading it to the applications of biomedical and functional foods for ameliorating chronic liver diseases resulted from a high-energy diet.

show abstract

Impaired hepatic removal of galectin–3 and association with worse liver function in patients with alcoholic liver cirrhosis

Cited by 12 publications

References 0 publications

Fecal and Urinary Adipokines as Disease Biomarkers

Fecal and Urinary Adipokines as Disease Biomarkers

The Impact of Obesity on the Excretion of Steroid Metabolites in Boys and Girls: A Comparison with Normal-Weight Children

Pectic Oligogalacturonide Facilitates the Synthesis and Activation of Adiponectin to Improve Hepatic Lipid Oxidation

Contact Info

Product

Resources

About